Disseminated　intravascular　coagulation　(DIC),　an　acute　syndrome　of　systemic　thrombus　formation　in　microvasculatures　throughout　the　body,　can　be　induced　by　severe　infections,　e.g.　sepsis.　Anticoagulants　are　clinically　used　to　alleviate　the　intensities　of　DIC.　However,　anticoagulants　only　reduce　the　thrombus　formation　but　have　negligible　effects　on　the　inflammatory　conditions.　We　previously　reported　embelin,　a　natural　product,　as　an　inhibitor　of　plasminogen　activator　inhibitor-1　(PAI-1),　suggesting　the　potent　antithrombotic　property.　In　this　study,　we　used　three　thrombotic　mice　models　to　confirm　the　antithrombotic　property　of　embelin.　By　combining　the　anti-inflammatory　and　the　antithrombotic　properties,　we　proposed　embelin　as　a　potent　therapeutic　agent　for　sepsis-induced　DIC,　which　involves　both　inflammation　and　thrombosis.　In　a　lipopolysaccharides-induced　septic　mice　model,　embelin　not　only　significantly　ameliorated　the　inflammation　levels,　but　also　effectively　reduced　the　pulmonary　hemorrhages　and　the　micro-thrombi　formations　in　lung.　In　contrast,　low-molecular-weight-heparin,　an　anticoagulant,　only　moderately　ameliorated　the　pulmonary　hemorrhages　and　thrombotic　obstructions,　but　had　non-measurable　effect　on　the　inflammatory　conditions.　In　addition,　embelin　alleviated　the　dysregulation　of　the　global　coagulation　in　septic　mice,　but　did　not　affect　the　global　coagulation　in　normal　mice.　Our　current　study　demonstrates　the　antithrombotic　property　of　embelin　and　the　potency　of　the　treatment　or　prevention　of　syndromes　combining　inflammation　and　thrombosis,　e.g.　sepsis-induced　DIC.